Drug profile · INN
eplontersen sodium
WAINUA (AUTOINJECTOR)
eplontersen sodium (WAINUA (AUTOINJECTOR)) is a transthyretin mrna antisense inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — eplontersen sodium
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 1
- Programs
- 3
- Data quality
- 0.84
Quick answer
eplontersen sodium (WAINUA (AUTOINJECTOR)) is a transthyretin mrna antisense inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Transthyretin mRNA antisense inhibitor
Primary target: Transthyretin mRNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is eplontersen sodium?
eplontersen sodium (WAINUA (AUTOINJECTOR)) is a transthyretin mrna antisense inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for eplontersen sodium?
WAINUA (AUTOINJECTOR) is a marketed brand name for eplontersen sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of eplontersen sodium?
eplontersen sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.